ARCHIVES

Was Dr. Bunn Insensitive Or Just Efficient? FDA Imbroglio Points To Larger Problems

This article is from The Cancer Letter archive.

Vol. 21 No. 43 | November 10, 1995

Download PDF Visit The Full Archive

Related Articles

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

April 25, 2014

Von Eschenbach Candidacy for FDA Hampered By Three Republican Holds.

December 1, 2006

Funding opportunities listed.

June 4, 2004

PhRMA’s New Ethics Code Prohibits Trinkets, Dinners; Speaking Fees Still OK.

July 11, 2008

DCT Board Insists On Being Heard In Development Of CCOP Guidelines

February 19, 1982

DCE Advisors Okay Study Of Cancer Risk in Breast Augmentation

November 22, 1991